Upstream Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ORBIMED ADVISORS LLC, was filed 17 Oct 2024.
Upstream Bio, Inc.: what insiders have been doing
Upstream Bio, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 16 November 2026, 17 filings were filed, from 5 insiders.
Only sales appear on the open market, 12 sales in all totalling €72k, filed by 5 insiders. Sutherland Everett Rand filed the largest sale, €17k, on 17 March 2026.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 3,183 companies tracked on its exchange, the median is 24 filings; at 17 filings, this issuer sits below that mark. Looking back to 2024, when coverage begins, insiders filed 3 purchases and 12 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.9 m USD and net income at -143.4 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and Drägerwerk AG & Co. KGaA also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -10.9%Entry US$25.88 · Close at T+365 US$23.05
- -10.9%Entry US$25.88 · Close at T+365 US$23.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Upstream Bio, Inc. Buy (bullish), based on 5 analysts. Average price target: US$21.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.
- 485 shares@ US$5.490.0017% mcap26.6% of flowCommon StockSEC:0001193125-26-394318:0
- 895 shares@ US$5.490.0032% mcap26.3% of flowCommon StockSEC:0001193125-26-394330:0
- 853 shares@ US$5.490.0030% mcap37.0% of flowCommon StockSEC:0001193125-26-394322:0
- 700 shares@ US$5.490.0025% mcap37.0% of flowCommon StockSEC:0001193125-26-394324:0
- 2,095 shares@ US$5.490.0074% mcap37.0% of flowCommon StockSEC:0001193125-26-394325:0
- 477 shares@ US$6.1028.9% of flowCommon StockSEC:0001193125-26-274119:0
- 895 shares@ US$6.1029.0% of flowCommon StockSEC:0001193125-26-274121:0
- 852 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111138:0
- 699 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111105:0
- 894 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111134:0
- 2,093 shares@ US$9.2963.0% of flowCommon StockSEC:0001193125-26-111124:0
- 475 shares@ US$9.2962.6% of flowCommon StockSEC:0001193125-26-111121:0
- 32,000 shares0Common StockSEC:0001193125-26-004757:0
- 25,000 shares0Common StockSEC:0001193125-26-004755:0
- 17,000 shares0Common StockSEC:0001193125-26-004756:0
- 30,500 shares0Common StockSEC:0001193125-26-004758:0
- 75,000 shares0Common StockSEC:0001193125-26-004754:0
- 660,000 shares@ US$17.0080.0% of flowCommon StockSEC:0000947871-24-000807:3Canonical exit: 13 Jan 2025 (T+90)
- 165,000 shares@ US$17.0020.0% of flowCommon StockSEC:0000947871-24-000807:1Canonical exit: 13 Jan 2025 (T+90)
- 2,887,833 sharesCommon StockSEC:0000947871-24-000806:2
- 3,147,000 sharesCommon StockSEC:0000950170-24-115295:1
- 1,172,410 sharesCommon StockSEC:0000950170-24-115295:2
- 2,887,833 sharesCommon StockSEC:0000947871-24-000807:2
- 660,000 shares@ US$17.0080.0% of flowCommon StockSEC:0000947871-24-000806:3Canonical exit: 13 Jan 2025 (T+90)
- 165,000 shares@ US$17.0020.0% of flowCommon StockSEC:0000947871-24-000806:1Canonical exit: 13 Jan 2025 (T+90)
25 of 29 declarations
About Upstream Bio, Inc.
Upstream Bio, Inc. is a company listed on the XNAS market, focused on developing innovative biological therapies. It aims to provide solutions for immunological and inflammatory diseases.
Written on 25 June 2026 from the filings and market data available that day. Live figures are in the blocks above.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendationsThe weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.
